New Orleans, Louisiana - Diets rich in mono-unsaturated fatty acids from plants were associated with a lower risk of dying from heart disease or other causes compared to diets rich in mono-unsaturated fats from animals, which were linked to a higher risk of death from heart disease or other causes, according to preliminary research presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2018, a premier global exchange of the latest advances in population based cardiovascular science for researchers and clinicians.

Dallas, Texas - The American Heart Association, the world’s leading voluntary health organization devoted to building healthier lives free of cardiovascular disease and stroke, has collaborated with Google to develop an augmented reality version of Hands-Only CPR training that launches today in the Association’s mobile App, My Cardiac Coach™.

Washington, DC - Today, we’re taking a key step forward in implementing the Drug Quality and Security Act (DQSA) and section 503B of the Federal Food, Drug, and Cosmetic Act. Among other things, these provisions limit the bulk drug substances that outsourcing facilities can use in compounding. It directs the FDA to develop a list of bulk drug substances for which there is a clinical need – the 503B bulks list.

Washington, DC - Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). The cells also re-establish their normal organization and function. The findings point to potential therapies for controlling inflammation and slowing progression of rare retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), the most common cause of blindness among Americans 50 and older. A report on the study was published online today in Science Advances. The NEI is part of the National Institutes of Health.

Washington, DC - When the U.S. Food and Drug Administration first warned Americans in May 2017 that lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the U.S., the agency made a commitment to continue to aggressively investigate the problem. Since then, the FDA has remained in close contact with the lead test manufacturer as well as Becton Dickinson (BD) & Company, the manufacturer of certain blood sample collection tubes often used alongside many lead tests, as part of our effort to determine the cause of the inaccurate results.

Washington, DC - Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide, allowing immune system cells called neutrophils to attack and kill the bacteria. The early stage, in vitro research was conducted by scientists at the National Institute of Allergy and Infectious Diseases’ (NIAID) Rocky Mountain Laboratories and the New Jersey Medical School-Rutgers University.